Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.

CArdioMetabolism and Atherosclerotic PlaqUe progreSsion (CAMPUS) study is a single center, prospective cohort study to investigate the impact of cardiometabolic factors on coronary diseases. This study consecutively enrolls patients with coronary artery diseases complicatied with metabolic abnormalities, including diabetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.

Inclusion Criteria:

• Age 18-80 years

• Established coronary artery disease or metabolic disorders, including:

  1. Type 2 diabetes diagnosed by one of the following criteria:

     HbA1c >/= 6.5% Fasting plasma glucose >/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT >/= 11.1 mmol/l Already receiving glucose-lowering agents

  2. Prediabetes

  3. Obesity

  4. Chronic kidney disease

  5. Hyperuricemia

  6. Dyslipidemia

Exclusion Criteria:

• Severe liver failure (Child-Pugh grade B to C)
• Severe anemia (hemoglobin < 60g/L)
• Familial hypercholesterolemia
• Active malignant tumor
• Active autoimmune diseases on corticosteroids
• Acute or chronic infection
• Life expectancy < 1 year

This study is a single-center cohort study. Patients with metabolic disorders (as listed in eligibility criteria) and suspected coronary artery disease undergone coronary angiography at Ruijin Hospital, Shanghai, China are consecutively enrolled.